Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [
]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's “home country”), or under the rules of the
home country exchange on which the registrant's securities are
traded, as long as the report or other document is not a press
release, is not required to be and has not been distributed to the
registrant's security holders, and, if discussing a material event,
has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibits 99.1 and 99.2 shall be incorporated by reference into the
Company's effective Registration Statements on Form F-3, as amended
and supplemented (Registration Statement Nos. 333-172796 and
333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
As previously reported by Intellipharmaceutics
International Inc. (the “Company”) in its report on Form 6-K filed with the
Securities and Exchange Commission on August 15, 2018, at the
special meeting of the shareholders of the Company held on
August 15, 2018, the Company’s shareholders granted the
Company’s Board of Directors (the “Board”)
discretionary authority to implement a consolidation of the issued
and outstanding common shares of the Company on the basis of a
consolidation ratio within a range from five (5) pre-consolidation
common shares for one (1) post-consolidation common share to 15
pre-consolidation common shares for one (1) post-consolidation
common shares of the Company, or the “reverse
split”.
The
Board has selected a share consolidation ratio of ten (10)
pre-consolidation shares for one (1) post-consolidation common
share. On September 12, 2018,
the Company filed an amendment to the Company’s articles
(“Articles of Amendment”) which
implemented the one-for-10 reverse split. The Company anticipates
that its common shares will begin trading on each of The NASDAQ
Capital Market (“Nasdaq”) and the Toronto Stock
exchange (“TSX”) on a post-split basis under the
Company’s existing trade symbol “IPCI” at the
market open on September 14, 2018. The new CUSIP number for the
Company’s common shares will be 458173309, and the new ISIN
will be CA4581733090. A copy of the Articles of Amendment is
attached as Exhibit 99.1 to this report and is incorporated herein
by reference.
On September 13, 2018, the Company issued a
press release announcing the one-for-10 reverse split. A copy of
the press release is attached as Exhibit 99.2 to this report and is
incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew Patient
|
|
Date:
September 13, 2018
|
Andrew
Patient
Chief Financial Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Articles
of Amendment to Articles of Intellipharmaceutics International
Inc.
|
|
99.2
|
News
Release dated September 13, 2018 - Intellipharmaceutics Announces
One-For-10 Reverse Stock Split
|